Jonathan P. Schneck
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2026
The mRNA lipid nanoparticles (LNPs) represent a new generation of vaccine carriers designed to elicit potent immune responses against infectious diseases and cancer. Despite the clinical success and rapid advancements in mRNA LNP technologies, the trafficking patterns of LNPs after intramuscular (i.m.) administration and the subsequent tissue-specific immunological effects have not been systematically characterized. Here, we report that trafficking of mRNA LNPs to different organs following i.m. injection is crucial for the induction of tissue-specific immunity beyond systemic immune response, particularly in tissue-resident CD8 + T cell generation, which is important for localized defense. By fine-tuning the composition of mRNA LNPs, trafficking patterns to systemic organs can be modulated, which can alter the resulting tissue-specific immune response. Formulations with a greater ability to enter the bloodstream can preferentially localize and transfect cells in specific organs like the liver, elicit stronger tissue-specific CD8 + T cell immune responses, and achieve enhanced efficacy in a liver tumor model. These findings highlight the potential to tailor mRNA LNP compositions to modulate trafficking following i.m. injection, thereby providing novel strategies for designing tissue-specific vaccines. Such strategies are particularly valuable for organ-specific diseases like cancer and infectious diseases, where tissue targeting and long-lasting immunity are essential for therapeutic success.
Year:
2025
Hydrogel materials have emerged as versatile platforms for various biomedical applications. Notably, the engineered nanofiber-hydrogel composite (NHC) has proven effective in mimicking the soft tissue extracellular matrix, facilitating substantial recruitment of host immune cells and the formation of a local immunostimulatory microenvironment. Leveraging this feature, here we report an mRNA lipid nanoparticle (LNP)-incorporated NHC microgel matrix, termed LiNx, by incorporating LNPs loaded with mRNA encoding tumour antigens. Harnessing the potent transfection efficiency of LNPs in antigen-presenting cells (APCs), LiNx demonstrates remarkable immune cell recruitment, antigen expression and presentation, and cellular interaction. These attributes collectively create an immunostimulating milieu and yield a potent immune response achievable with a single dose, comparable to the conventional three-dose LNP immunization regimen. Further investigations reveal that the LiNx not only generates heightened Th1 and Th2 responses but also elicits a distinctive Type 17 T helper cell-mediated response pivotal for bolstering antitumour efficacy. Our findings elucidate the mechanism underlying LiNx’s role in potentiating antigen-specific immune responses, presenting a new strategy for cancer immunotherapy.
Year:
2025
Antigen‐presenting cells (APCs), such as dendritic cells and macrophages, have a unique ability to survey the body and present information to T cells via peptide‐loaded major histocompatibility complexes (signal 1). This presentation, along with a co‐stimulatory signal (signal 2), leads to activation and subsequent expansion of T cells. This process can be harnessed and utilized for therapeutic applications, but the use of patient‐derived APCs can be complex and inefficient. Alternatively, artificial APCs (aAPCs) provide a simplified method to achieve T cell activation by presenting the two necessary stimulatory signals. This protocol describes the utilization of magnetic nanoparticles and stimulatory proteins to create aAPCs that can be employed for activating and expanding antigen‐specific T cells for both basic and translational immunology and immunotherapy studies. © 2024 Wiley Periodicals LLC. Basic Protocol 1 : Protein and particle modification for aAPC fabrication Basic Protocol 2 : aAPC validation by immunolabeling of conjugated protein Support Protocol 1 : Quantification of aAPC stock concentration Basic Protocol 3 : Determination of aAPC usage for murine CD8 + T cell activation Support Protocol 2 : Isolation of murine CD8 + T cells
Year:
2024
Tissue-resident memory T (T RM ) cells preferentially reside in peripheral tissues, serving as key players in tumor immunity and immunotherapy. The lack of effective approaches for expanding T RM cells and delivering these cells in vivo hinders the exploration of T RM cell–mediated cancer immunotherapy. Here, we report a nanoparticle artificial antigen-presenting cell (nano-aAPC) ex vivo expansion approach and an in vivo delivery system for T RM cells. Using the nano-aAPC platform, we expanded functional antigen-specific murine and human T RM -like CD8 + T cells ex vivo. We also developed an injectable macroporous hyaluronic acid (HA) hydrogel to deliver T RM -like cells. T RM -like cells delivered in the optimized HA hydrogel trigger robust local and systemic antitumor immunity and show synergistic effects with anti–PD-1 treatment. Our findings suggest that nano-aAPC–induced T RM -like cells, coupled with a hydrogel delivery system, offer an efficient way to advance the understanding of T RM cell–mediated cancer therapy.
Year:
2024
Collaborators (9)
Maximilian F Konig
Director, Cellular Therapy Program (Autoimmunity)
Johns Hopkins University School of Medicine
Joshua Doloff
Associate Professor
Johns Hopkins University
Sean C. Murphy
Professor
University of Washington
Christine Wei
Johns Hopkins University
Savannah Est-Witte
Assistant Research Professor
Johns Hopkins University
Sashank K. Reddy
Johns Hopkins University
Stephany Y Tzeng
Associate Research Professor
Johns Hopkins University
John Hickey
Assistant Professor
Duke University
Hai‐Quan Mao
Professor
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.